Summary:
Revvity, Inc. has launched EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG), the first assay validated for dried blood spot (DBS) samples, to enhance measles diagnosis and immunity assessment.
Takeaways:
- Increased Testing Access – The new ELISA test supports both traditional and DBS samples, improving measles virus surveillance and prevention.
- DBS Advantages – Dried blood spot sampling is minimally invasive, stable, and practical for use in routine testing and regions with limited medical infrastructure.
- Filling a Diagnostic Gap – This assay provides an IVDR-compliant solution for measles IgG detection, eliminating the need for independent DBS validation by labs.
Revvity, Inc., has announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma.
Measles: Highly Contagious and on the Rise
Measles is a highly contagious airborne disease that can lead to severe complications for infected individuals. With cases on the rise globally, improving and expanding access to testing for the measles virus supports broad surveillance and prevention efforts.
Diagnostics using DBS only require droplets of capillary blood to provide a reliable test result. Samples are typically taken from the fingertip and deposited onto a paper card, which can then be sent to a diagnostic laboratory for further analysis. Due to the minimally invasive sampling method and high stability of the sample, diagnostics using DBS are beneficial in routine testing, for use in studies, or in regions without developed medical infrastructure.
The possibility of using DBS instead of venous blood samples expands opportunities for practitioners as well as diagnostics laboratories investigating these infections.
“Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution,” explains . Lars Komorowski, PhD, chief scientific officer of EUROIMMUN.
The Anti-Measles Virus ELISA 2.0 (IgG) can be processed manually or automatically using EUROIMMUN‘s scalable solutions available for DBS processing and ELISA.
Featured Image: EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG), is validated for DBS samples, to enhance measles diagnosis and immunity assessment. Photo: Revvity
